Language:

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2013-08, Vol.369 (8), p.699-710 [Peer Reviewed Journal]

Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1215734 ;PMID: 23964932 ;CODEN: NEJMAG

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Author: Feagan, Brian G ; Rutgeerts, Paul ; Sands, Bruce E ; Hanauer, Stephen ; Colombel, Jean-Frédéric ; Sandborn, William J ; Van Assche, Gert ; Axler, Jeffrey ; Kim, Hyo-Jong ; Danese, Silvio ; Fox, Irving ; Milch, Catherine ; Sankoh, Serap ; Wyant, Tim ; Xu, Jing ; Parikh, Asit
Subjects: Adult ; Aged ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - pharmacokinetics ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects/pharmacokinetics/therapeutic use ; Biological and medical sciences ; Bleeding ; Cell adhesion & migration ; Clinical trials ; Colitis, Ulcerative - drug therapy ; Double-Blind Method ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Gastroenterology & hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastroentérologie & hépatologie ; General aspects ; Glucocorticoids - therapeutic use ; Human health sciences ; Humans ; Immunosuppressive Agents - therapeutic use ; Induction Chemotherapy ; Induction therapy ; Infections ; Inflammatory bowel disease ; Integrins - antagonists & inhibitors ; Integrins - immunology ; Integrins/antagonists & inhibitors/immunology ; Maintenance Chemotherapy ; Male ; Medical research ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Patients ; Rectum ; Remission ; Sciences de la santé humaine ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Ulcerative colitis
Is Part Of: The New England journal of medicine, 2013-08, Vol.369 (8), p.699-710
Description: In this 52-week randomized trial, the α 4 β 7 integrin antibody vedolizumab was effective in treating ulcerative colitis. There were not significantly more adverse events with vedolizumab than with placebo, but the trial was not large or long enough to fully assess safety. Ulcerative colitis is a chronic inflammatory bowel disease characterized by symptoms of bloody diarrhea, abdominal cramps, and fatigue. 1 Current medical therapy has important limitations. Aminosalicylates 2 – 4 are only modestly effective; glucocorticoids can cause unacceptable adverse events and do not provide a benefit as maintenance therapy. Tumor necrosis factor (TNF) antagonists, although efficacious, 5 , 6 predispose patients to serious infection. 7 Thus, new treatment strategies are needed. The migration of leukocytes into inflamed intestinal tissue is highly regulated by specific molecular mechanisms. The α 4 β 7 integrin, 8 a cell-surface glycoprotein variably expressed on circulating B and T lymphocytes, interacts with mucosal addressin-cell . . .
Publisher: Waltham, MA: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
ISSN: 1533-4406
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1215734
PMID: 23964932
CODEN: NEJMAG
Source: ProQuest One Psychology
MEDLINE
Alma/SFX Local Collection
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1215734 ;PMID: 23964932 ;CODEN: NEJMAG

Searching Remote Databases, Please Wait